Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions

BACKGROUND: In this study, we investigated the efficacy of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients harboring favorable mutations regarding the progressive disease (PD) status with appearance of indolent new l...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Ping-Chih, Chiu, Li-Chung, Li, Shih-Hong, Chen, Chih-Hung, Wang, Chih-Liang, Kao, Kuo-Chin, Chang, John Wen-Chang, Wang, Chih-Wei, Yu, Chih-Teng, Chung, Fu-Tsai, Yang, Cheng-Ta, Liu, Chien-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chang Gung University 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140297/
https://www.ncbi.nlm.nih.gov/pubmed/27372167
http://dx.doi.org/10.1016/j.bj.2015.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140297/
https://www.ncbi.nlm.nih.gov/pubmed/27372167
http://dx.doi.org/10.1016/j.bj.2015.07.002

Ejemplares similares